Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Percheron Therapeutics ( (AU:PER) ) has shared an update.
Percheron Therapeutics Limited has announced a change in the interest of its director, Charmaine Gittleson, in the company’s securities. The change involves the acquisition of 239,999 unquoted options exercisable at 3.5 cents per option, issued under the company’s Bonus Offer. This adjustment in the director’s interest reflects the company’s ongoing strategic initiatives to align its leadership’s interests with its operational goals.
The most recent analyst rating on (AU:PER) stock is a Buy with a A$0.24 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
More about Percheron Therapeutics
Average Trading Volume: 4,227,335
Technical Sentiment Signal: Sell
Current Market Cap: A$10.87M
For a thorough assessment of PER stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue